Direct block of human ether-a-go-go-related gene potassium channels by caffeine

S L Cockerill1, J S Mitcheson

  • 1Department of Cell Physiology and Pharmacology, University of Leicester, UK.

Insights

Caffeine inhibits human ether-a-go-go-related gene (hERG) potassium channels by directly blocking the pore, not via calcium or cAMP pathways. High caffeine doses are unlikely to cause cardiac arrhythmias in humans.

Area of Science:

  • Cardiovascular Pharmacology
  • Molecular Physiology
  • Ion Channel Biology

Background:

  • The human ether-a-go-go-related gene (hERG) potassium channel is crucial for cardiac repolarization.
  • hERG channel dysfunction is linked to potentially fatal arrhythmias like long QT syndrome.
  • Caffeine is a common tool to investigate cellular signaling pathways.

Purpose of the Study:

  • To investigate the mechanism by which caffeine affects hERG channel function.
  • To determine if caffeine's effects on hERG are mediated by intracellular calcium or cAMP.
  • To assess the potential for dietary caffeine to induce cardiac arrhythmias.

Main Methods:

  • Patch-clamp electrophysiology was used to measure hERG currents in HEK293 cells.
  • Experiments involved manipulating intracellular calcium and cAMP levels.
  • Site-directed mutagenesis of the hERG channel pore was performed.

Main Results:

  • 5 mM caffeine rapidly and reversibly inhibited hERG currents to 61.1% of control.
  • Caffeine's inhibitory effect was independent of cAMP levels and intracellular calcium.
  • Caffeine directly blocked the hERG channel in an open state-dependent manner, with pore mutations reducing block.
  • Caffeine likely binds to a site within the channel's inner cavity.

Conclusions:

  • Caffeine inhibits hERG currents through direct pore block, not via calcium or cAMP signaling.
  • Dietary caffeine concentrations are too low to significantly impact hERG function and cause long QT syndrome.
  • The findings have implications for using caffeine as a research tool in cells expressing hERG channels.

Related Concept Videos

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers01:12

Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers

Class III antiarrhythmic drugs are a group of medications that can prolong action potentials in the heart. They achieve this by blocking potassium channels or enhancing inward currents from sodium channels. However, these drugs have a unique property of "reverse use-dependence," which is most pronounced at slower heart rates and can lead to torsades de pointes—a specific type of arrhythmia. However, it is essential to note that excessive QT interval prolongation—a measure of the heart's...
Depolarizing Blockers: Mechanism of Action01:28

Depolarizing Blockers: Mechanism of Action

Depolarizing blockers act on skeletal muscle fibers' membranes and induce their depolarization. Most depolarizing blockers have two quaternary N+ atoms that bind the nicotinic acetylcholine receptors and cause neuromuscular blockade within minutes.
Succinylcholine is the most commonly used depolarizing blocker. Chemically, it constitutes two molecules of acetylcholine joined together by an acetate methyl group. They act on the receptors in the same way as acetylcholine. Because succinylcholine...
G-Protein Gated Ion Channels01:21

G-Protein Gated Ion Channels

GPCRs are primarily responsible for our sense of smell, taste, and vision.  The binding of a sensory stimulus activates GPCR to stimulate effector proteins, many of which are ion channels in the sensory organs. GPCRs modulate the opening and closing of the target ion channels either directly by binding them, or by releasing second messengers that activate these channels. As ions move across the membrane, the membrane potential is altered, which induces an appropriate response.
Sensory organs,...
Depolarizing Blockers: Pharmocokinetics01:19

Depolarizing Blockers: Pharmocokinetics

Depolarizing blockers are administered through intravenous injection. Succinylcholine is the most common choice of depolarizing blockers in emergency clinical practices. Although they have a rapid onset, they readily diffuse away from the motor end plate into the extracellular fluid. They are metabolized by enzymes such as liver butyrylcholinesterase and plasma pseudocholinesterases. This produces a short duration of action, typically 5-10 minutes long, unlike nondepolarizing blockers, which...
Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers01:22

Antiarrhythmic Drugs: Class I Agents as Sodium Channel Blockers

Class I antiarrhythmic drugs are used to treat various types of arrhythmias or irregular heart rhythms. These drugs block the sodium (Na+) channels in the cardiac cells, thereby affecting the movement of electrical impulses across the heart. Class I antiarrhythmic drugs are divided into three subgroups: Class IA, Class IB, and Class IC, each with distinct mechanisms of action and effects on the heart.
Class 1A Antiarrhythmic Drugs: These drugs work by moderately blocking sodium channels,...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...